ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015
May 26 2015 - 9:00AM
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on innovative treatments that address unmet medical
needs in neurological and related central nervous system disorders,
today announced that it will present at the Jefferies 2015
Healthcare Conference on Tuesday, June 2, 2015, at 1:30 p.m.
Eastern Time in New York City.
A live webcast of ACADIA’s presentation will be accessible on
the company’s website, www.acadia-pharm.com, under the investors
section and an archived recording will be available on the website
through June 16, 2015.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by
NUPLAZID™ (pimavanserin), for which we have reported positive Phase
III trial results in Parkinson’s disease psychosis and which has
the potential to be the first drug approved in the United States
for this disorder. Pimavanserin is also in Phase II development for
Alzheimer’s disease psychosis and has successfully completed a
Phase II trial in schizophrenia. ACADIA also has clinical-stage
programs for chronic pain and glaucoma in collaboration with
Allergan, Inc. All product candidates are small molecules that
emanate from internal discoveries. ACADIA maintains a website at
www.acadia-pharm.com to which we regularly post copies of our press
releases as well as additional information and through which
interested parties can subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
progress and timing of ACADIA’s drug discovery and development
programs, either alone or with a partner, including clinical
trials, the benefits to be derived from ACADIA’s product
candidates, in each case including NUPLAZID (pimavanserin), and the
potential for NUPLAZID to be the first drug approved in the United
States for Parkinson’s disease psychosis. These statements are only
predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development, approval and
commercialization, and collaborations with others, and the fact
that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year
ended December 31, 2014 as well as ACADIA’s subsequent filings with
the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150526005154/en/
ACADIA Pharmaceuticals Inc.Steve Davis, Interim Chief Executive
OfficerLisa Barthelemy, Director of Investor Relations(858)
558-2871
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024